Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2013

Conditions

Asthma

Interventions

DRUG

BI 54903 MD

2 puffs b.i.d. via Respimat inhaler

DRUG

Placebo matching Respimat

2 puffs a.m. via Respimat inhaler

DRUG

Placebo matching Respimat

2 puffs a.m. via Respimat inhaler

DRUG

BI 54903

2 puffs LD b.i.d. via Respimat inhaler